Bruton's tyrosine kinase (BTK) is emerging as a promising therapeutic target in asthma because of its central role in mast cell, basophil, eosinophil, and B cell activation.1 Several BTK inhibitors, including rilzabrutinib, are under investigation in early-phase clinical trials for asthma, but none are currently approved or established as standard therapy for this indication. Rilzabrutinib is being developed for several immune-mediated diseases, including asthma, with preclinical data supporting its immunomodulatory effects on B cells, mast cells, basophils, and other innate immune cells relevant to asthma pathogenesis.
The Lancet Respiratory Medicine published a clinical update in Critical Care on 02 Apr 2026. The item focuses on Rilzabrutinib and the evolving landscape of oral therapies for uncontrolled asthma. Open the detail page to review the full original feed content.